Skip to main content
main-content

03-06-2019 | Gastrointestinal cancer | Video

ASCO 2019: Olaparib maintenance improves BRCA1/2-positive pancreatic cancer outcomes

Hedy Kindler presents the phase III POLO trial of maintenance therapy with the PARP inhibitor olaparib in metastatic pancreatic cancer patients harbouring germline mutations in BRCA1 or BRCA2 (3:47).

Funding for independent interviews at ASCO 2019 was provided in part by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits